Cardiometabolic Therapeutics Market
完整報告名稱與涵蓋範圍
Cardiometabolic Therapeutics Market Size, Share & Trends Analysis Report, By Drug Class (Incretin-Based Therapies (GLP-1 and Multi-Agonists), SGLT2 Inhibitors, Lipid-Lowering Agents (PCSK9, Lp(a) and Novel Targets), Antihypertensives and Renal-Protective Agents, Heart Failure and Cardiovascular Outcome Therapies), By Indication (Type 2 Diabetes, Obesity, Atherosclerotic Cardiovascular Disease, Heart Failure and Chronic Kidney Disease, Metabolic Liver Disease), By Route of Administration (Oral, Injectable), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The cardiometabolic therapeutics market covers prescription medicines that treat the interlinked disorders of obesity, type 2 diabetes, atherosclerotic cardiovascular disease, heart failure, chronic kidney disease and metabolic liver disease, spanning incretin therapies, SGLT2 inhibitors, novel lipid-lowering agents, renal-protective and heart-failure therapies. Generic statins and older antihypertensives are included at the class level for volume context but the value analysis concentrates on patented and recently launched products.
The field has been reorganised around drug classes that deliver outcomes across several organ systems: incretin therapies reducing cardiovascular events in obesity, SGLT2 inhibitors extending from diabetes into heart failure and kidney disease, and antisense and siRNA agents targeting lipoprotein(a) and other residual risk factors. Sponsors are pursuing oral incretins, long-acting formulations, fixed-dose combinations and outcomes trials that justify broad reimbursement, while payers grapple with the budget impact of treating tens of millions of eligible patients. Biosimilar and generic entry for older agents, and price negotiations in the United States, temper class-level growth.
North America and Europe dominate value, while China and India represent the largest volume growth given prevalence trends. Competition is led by a small group of diversified cardiometabolic franchises, with specialist companies contributing lipid, liver and kidney assets.
The InsightAce study supplies US$ forecasts for all drug class, indication, route of administration and distribution channel and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cardiometabolic Therapeutics Market Snapshot
Chapter 4. Global Cardiometabolic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. Drug Class & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Drug Class:
5.2.1. Incretin-Based Therapies (GLP-1 and Multi-Agonists)
5.2.2. SGLT2 Inhibitors
5.2.3. Lipid-Lowering Agents (PCSK9, Lp(a) and Novel Targets)
5.2.4. Antihypertensives and Renal-Protective Agents
5.2.5. Heart Failure and Cardiovascular Outcome Therapies
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Type 2 Diabetes
6.2.2. Obesity
6.2.3. Atherosclerotic Cardiovascular Disease
6.2.4. Heart Failure and Chronic Kidney Disease
6.2.5. Metabolic Liver Disease
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. Route of Administration & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Route of Administration:
7.2.1. Oral
7.2.2. Injectable
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Cardiometabolic Therapeutics Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Novo Nordisk A/S
11.2. Eli Lilly and Company
11.3. AstraZeneca plc
11.4. Boehringer Ingelheim International GmbH
11.5. Amgen Inc.
11.6. Novartis AG
11.7. Merck & Co., Inc.
11.8. Bayer AG
11.9. Pfizer Inc.
11.10. Sanofi
11.11. Regeneron Pharmaceuticals, Inc.
11.12. Daiichi Sankyo Company, Limited
11.13. Esperion Therapeutics, Inc.
11.14. Madrigal Pharmaceuticals, Inc.
11.15. Ionis Pharmaceuticals, Inc.
圖表清單 List of Tables & Figures
Table 1. Global Cardiometabolic Therapeutics Revenue Forecast by Drug Class, 2026-2035 (US$ Mn)
Figure 1. Global Cardiometabolic Therapeutics Market Snapshot, 2026 & 2035
Table 2. Global Cardiometabolic Therapeutics Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Cardiometabolic Therapeutics Market Share by Indication, 2026 & 2035
Table 3. Global Cardiometabolic Therapeutics Revenue Forecast by Route of Administration, 2026-2035 (US$ Mn)
Figure 3. Cardiometabolic Drug Class Convergence Across Diabetes, Obesity, Heart Failure and Kidney Disease
Table 4. Global Cardiometabolic Therapeutics Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Outcomes-Trial Readout Calendar and Label Expansion Timeline, 2026-2030
Table 5. North America Cardiometabolic Therapeutics Revenue by Country, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Cardiometabolic Therapeutics Growth Opportunity Analysis
Table 6. Europe Cardiometabolic Therapeutics Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Payer Budget Impact Scenarios for Broad Incretin Coverage
Table 7. Asia Pacific Cardiometabolic Therapeutics Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Competitive Positioning of Key Cardiometabolic Therapeutics Market Participants
Table 8. Latin America and Middle East & Africa Cardiometabolic Therapeutics Revenue Forecast, 2026-2035 (US$ Mn)
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們